

Jaypirca™ (Pirtobrutinib) Prior Authorization Form

Member Name: _____ Date of Birth: _____ Member ID#: _____

Drug Information

Pharmacy Billing (NDC: _____) Start Date (or date of next dose): _____

Dose: _____ Regimen: _____

Billing Provider Information

Pharmacy NPI: _____ Pharmacy Name: _____

Pharmacy Phone: _____ Pharmacy Fax: _____

Prescriber Information

Prescriber NPI: _____ Prescriber Name: _____

Prescriber Phone: _____ Prescriber Fax: _____ Specialty: _____

Criteria**For Initial Authorization:****1. Please indicate the diagnosis and information:** **Chronic Lymphocytic/Small Lymphocytic Lymphoma (CLL/SLL)**A. Has member received ≥ 2 lines of systemic therapy, including a Bruton's kinase (BTK) inhibitor and a BCL-2 inhibitor? Yes No **Mantle Cell Lymphoma (MCL)**A. Does member have relapsed or refractory disease after ≥ 2 lines of systemic therapy? Yes No B. Does member's previous treatment include a Bruton's tyrosine kinase (BTK) inhibitor (e.g., acalabrutinib, ibrutinib, zanubrutinib)? Yes No **If diagnosis is not listed above, please indicate diagnosis:** _____

Additional Information: _____

For Continued Authorization:

1. Date of last dose: _____

2. Does member have any evidence of progressive disease while on pirtobrutinib? Yes No 3. Has the member experienced adverse drug reactions related to pirtobrutinib therapy? Yes No

If yes, please specify adverse reactions: _____

Prescriber Signature: _____ Date: _____

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays.Fax completed prior authorization request form to
888-601-8461 or submit Electronic Prior Authorization
through CoverMyMeds® or SureScripts.All requested data must be provided. Incomplete forms or
forms without the chart notes will be returned. Pharmacy
Coverage Guidelines are available at
AetnaBetterHealth.com/Oklahoma.**CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.